NCT06958120

Brief Summary

Group (A): This group will receive fentanyl infusion at a dose of (0.5μg/kg/h) all through the whole operation plus ultrasound guided bilateral superficial parasternal intercostal Plane block which will be done by injecting 0.4ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) at each side3. Group (B): This group will receive fentanyl infusion at a dose of (0.5μg/kg/h) all through the whole operation plus Ultrasound guided bilateral ESPB which will be done by injecting 0.4ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) at each side .

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jun 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 25, 2025

Completed
11 days until next milestone

First Posted

Study publicly available on registry

May 6, 2025

Completed
26 days until next milestone

Study Start

First participant enrolled

June 1, 2025

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2026

Completed
Last Updated

May 13, 2025

Status Verified

May 1, 2025

Enrollment Period

6 months

First QC Date

April 25, 2025

Last Update Submit

May 10, 2025

Conditions

Keywords

CHDRegional anaesthesiaPain management

Outcome Measures

Primary Outcomes (1)

  • Pain assessment

    Pain was assessed by the pediatric observational 10-point scale "Face, Leg, Activity, Cry, Consolability (FLACC) pain score.

    Immediately after admission to ICU then at 60 min, 2 hours, 4 hours, 8 hours and 12 hours postoperatively

Study Arms (2)

Superficial parasternal intercostal Plane block group

EXPERIMENTAL

This group will receive fentanyl infusion at a dose of (0.5μg/kg/h) all through the whole operation plus ultrasound guided bilateral superficial parasternal intercostal Plane block

Procedure: superficial parasternal intercostal Plane block

Erecto-Spinea plane block group

EXPERIMENTAL

This group will receive fentanyl infusion at a dose of (0.5μg/kg/h) all through the whole operation plus Ultrasound guided bilateral Erecto-Spinea plane block

Procedure: Erecto spinea plane block

Interventions

A high-frequency linear transducer was used to guide the insertion of a needle 2 cm lateral to the sternum. After identifying key anatomical structures, the needle was advanced in-plane into the pectointercostal fascial plane between the pectoralis major and internal intercostal muscle. Correct placement was confirmed with a saline injection, and then a local anesthetic (0.4 ml/kg of a 1:1 mix of bupivacaine 0.25% and lidocaine 1%) was injected bilaterally at the second and fourth ribs.

Superficial parasternal intercostal Plane block group

Using ultrasound, a needle is inserted near the T5 vertebra into the plane beneath the erector spinae muscle. After confirming correct positioning with saline, a local anesthetic mixture is injected in the fascial plane.

Erecto-Spinea plane block group

Eligibility Criteria

Age6 Months - 4 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • RACHS-1: Categories 1, 2 and 3
  • Patients undergoing corrective cardiac surgeries with midline sternotomy incision.
  • Redo surgeries.

You may not qualify if:

  • Patients whose parents or legal guardians refuse to participate.
  • Preoperative mechanical ventilation.
  • Preoperative inotropic drug infusion.
  • Coagulopathy.
  • Allergy to any of the studied drugs.
  • Severe pulmonary hypertension (\> 70 mmHg).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Abu Al reesh hospital

Cairo, Egypt

Location

MeSH Terms

Conditions

Heart Defects, CongenitalAgnosia

Condition Hierarchy (Ancestors)

Cardiovascular AbnormalitiesCardiovascular DiseasesHeart DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesPerceptual DisordersNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant professor

Study Record Dates

First Submitted

April 25, 2025

First Posted

May 6, 2025

Study Start

June 1, 2025

Primary Completion

December 1, 2025

Study Completion

February 1, 2026

Last Updated

May 13, 2025

Record last verified: 2025-05

Data Sharing

IPD Sharing
Will share

yes

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
2026
Access Criteria
Any

Locations